In this way, cell surface receptors largely characterize cell responsiveness to CAP in modulating cellular redox imbalance, determining the spectrum of cancers feasible for receiving CAP treatment, and explaining the anti-cancer efficacy of this emerging redox modulating tool for aggressive cancers. Here, CD177 is linked to cancer.